Meeting
2021 ASCO Annual Meeting
The equivalency study of novel current standard 3-drugs combination regimen (ondansetron, dexamethasone and olanzapine) to netupitant containing regimen for preventing high dose cisplatin induce nausea and vomiting treatment, double blind placebo control trial.
Authors
Chalermchai Lertanansit
Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Chalermchai Lertanansit , Wasamol Mahaparn , Virote Sriuranpong , Piyada Sitthideatphaiboon , Nattaya Sintawichai , Suebpong Tanasanvimon , Chanida Vinayanuwattikun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
TCTR20190508001
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 12100)
DOI
10.1200/JCO.2021.39.15_suppl.12100
Abstract #
12100
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.
First Author: Veerisa Vimolchalao
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2021 ASCO Annual Meeting
Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.
First Author: Zhigang Liu